Brian Callaghan, M.D., M.S.
Fovette E. Dush Early Career Professor of Neurology
Associate Professor, Neurology
Co-Division Chief, Neuromuscular
Eva L. Feldman, M.D., Ph.D. Professorship
Skip to content
A new analysis from the Institute for Clinical and Economic Review said the evidence available to date shows moderate effectiveness of two newer drugs for myasthenia gravis—eculizumab and efgartigimod—but found their price exceedingly high and their use not cost-effective.